Longevity Research Stack — Mitochondrial & Cellular Ageing Peptides
Reviewed by the BestHealingPeptides Editorial Team ·
Combine mechanistically distinct longevity-research peptides — mitochondrial-derived humanin (Bax/Bak inhibition, cytoprotection) and MOTS-c (AMPK activation, metabolic), pharmacological cardiolipin-stabilising SS-31 (cristae architecture preservation), and pineal-derived telomerase-modulating epitalon — to explore integrated effects on the mitochondrial-dysfunction, replicative-senescence, and cellular-ageing framework of ageing biology in pre-clinical models.
Components
SS-31 (Elamipretide)
longevity · regeneration
Humanin
longevity · immune
MOTS-c
metabolic · longevity
Epitalon
regeneration
Protocol notes
This is a research-only stack. None of the components is licensed as a medicine in the UK; combined administration to humans outside authorised clinical-trial frameworks engages the Human Medicines Regulations 2012. SS-31 has the deepest clinical-trial safety record among the components through the Stealth BioTherapeutics Phase III programme. Humanin, MOTS-c, and epitalon are pre-clinical or early-phase clinical research compounds. This stack reflects the emerging pharmacological space around mitochondrial-dysfunction longevity research; it does NOT represent a validated clinical intervention for age-related decline.
Mechanistic rationale — mitochondrial-dysfunction longevity framework
The longevity research pharmacology space is organised around several convergent mechanisms addressing the cellular-ageing phenotype. Mitochondrial dysfunction — reduced cristae organisation, cardiolipin peroxidation, decreased oxidative phosphorylation efficiency, increased ROS leak — is a central feature of ageing that connects to broader phenotypes including cellular senescence, impaired autophagy, and metabolic dysregulation. SS-31 (elamipretide) directly addresses cristae architecture through cardiolipin binding, preserving mitochondrial structural integrity. Humanin and MOTS-c are mitochondrial-derived peptides whose plasma concentrations decline with age and whose supplementation restores cytoprotective (humanin) and metabolic-regulatory (MOTS-c) functions of youth. Epitalon addresses the telomerase and replicative-senescence axis (with the Khavinson group's characterisation limitations noted in the epitalon profile). The four peptides target the mitochondrial-dysfunction, cytoprotective, metabolic-homeostasis, and telomerase axes simultaneously — mechanistically complementary rather than redundant, providing a research-framework toolkit for exploring the pharmacology of the cellular-ageing phenotype.
Component selection considerations
For mitochondrial-dysfunction research: SS-31 is the pharmacologically most-characterised choice with the broadest Phase III clinical safety data. Native humanin has more limited potency in pre-clinical work; HNG (S14G-humanin) is the higher-potency research analogue and should be specified when reproducing published literature. MOTS-c is well-characterised metabolically but less-studied in longevity contexts specifically. Epitalon is the historically most-visible longevity research peptide but has the mechanistic and evidence-base limitations characterised in its dedicated profile (single-network sourcing). The four-component stack is pharmacologically rational but produces a complex research protocol requiring multiple parenteral administration routes and careful protocol design. Simplified two- or three-component subsets targeting specific mechanistic questions (SS-31 + humanin for mitochondrial cytoprotection; MOTS-c + epitalon for metabolic-longevity intersection) may be more research-tractable for specific hypotheses.
Endpoint suggestions
Mitochondrial endpoints: Seahorse extracellular flux for OCR/ECAR in cell culture or ex-vivo tissue; high-resolution respirometry (Oroboros) for complex-specific respiratory chain assessment; TMRM or JC-1 fluorescent probes for mitochondrial membrane potential; electron microscopy for cristae structure; cardiolipin lipidomics for structural cardiolipin analysis; mtDNA copy number by qPCR. Cellular-ageing endpoints: SA-β-galactosidase staining for cellular senescence; SASP cytokines (IL-6, IL-8, MCP-1) for senescence-associated inflammatory phenotype; telomere length by qPCR or telomere restriction fragment analysis; hTERT expression. Behavioural and functional endpoints in aged-rodent models: exercise capacity (treadmill endurance), cognitive testing (Morris water maze, novel object recognition), body composition (DEXA), and inflammatory markers (hsCRP, IL-6). Plasma biomarkers of ageing: circulating humanin, MOTS-c, IGF-1, and inflammatory panels for tracking pharmacodynamic response. The endpoint selection should match the specific pathway being researched rather than attempting to characterise all pathways simultaneously — the four peptides can be researched in individual-component context or combined-component context, but comprehensive multi-endpoint studies require substantial resource allocation.
Where to source research peptides for laboratory research
The following UK-based suppliers stock research-grade, lyophilised peptides for in-vitro and pre-clinical work. Purity and provenance vary; always request a Certificate of Analysis (CoA) and confirm cold-chain storage on arrival. None of the products linked below are approved for human use.
- PeptideAuthority.co.uk
UK-based research peptide supplier with batch certificates of analysis and >99% purity testing.
- PeptideBarn.co.uk
Wide catalogue of research-grade lyophilised peptides shipped from the UK, including bulk vials.